Correction: Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis

There is an error in affiliation 4 for author Shuo Kang. The correct affiliation 4 is: Medical Insurance Office, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China.
Reference
Citation: Yang S, Hou Y, Wang X, Kang S, Pan Z (2026) Correction: Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis. PLoS One 21(7): e0353864. https://doi.org/10.1371/journal.pone.0353864
Published: July 14, 2026
Copyright: © 2026 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.